The commentary by Babar and Scahill on the role of pharmacoeconomics in developing countries has initiated a thought-provoking debate. I concur with the authors' viewpoints and would like to use this forum to address some key issues raised by the original article and the correspondence published so far.The authors proposed a conceptual model to assist in the determination of the need for and benefit from pharmacoeconomic methods in developing countries.However, Shafie and Hassali criticized the model on a number of points that were subsequently addressed by Babar and Scahill. My impression is that Shafie and Hassali misinterpreted the point Babar and Scahill were making with this model; the intention of the authors is to provide the basis of what could be developed into a robust index
展开▼
